

Altus Pharmaceuticals Inc.
Form 8-K
March 19, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

March 14, 2008

Altus Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

0-51711

(Commission
File Number)

04-3573277

(I.R.S. Employer
Identification No.)

640 Memorial Drive, Cambridge,
Massachusetts

(Address of principal executive offices)

02139

(Zip Code)

Registrant's telephone number, including area code:

617-299-2900

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 1.01 Entry into a Material Definitive Agreement.

In August 2006, we entered into a drug production and clinical supply agreement with Althea Technologies, Inc., or Althea. Under this agreement, Althea agreed to modify an existing production facility, and test and validate its manufacturing operations for the production of ALTU-238. The agreement provides for the production of a defined number of manufacturing runs of ALTU-238, from which we intend to supply planned clinical trials. Under the agreement, the parties agreed to prepare a definitive manufacturing project plan and schedule for these activities. The agreement was amended on June 25, 2007.

On March 14, 2008, the parties executed a second amendment to the agreement that sets forth a modified manufacturing plan and schedule for the project. In addition, Althea has agreed to reserve its production facility for an additional period of time at a specified price and the parties reset the defined number of manufacturing runs. The parties also agreed to revise the term of the agreement, so that it expires on the earlier of March 31, 2010 or until the production and delivery of a specified number of batches of drug product.

The foregoing is a summary description of certain terms of the second amendment. Altus intends to file the second amendment as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending March 31, 2008.

Edgar Filing: Altus Pharmaceuticals Inc. - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

March 19, 2008

Altus Pharmaceuticals Inc.

By: *Jonathan I. Lieber*

Name: Jonathan I. Lieber

Title: Vice President, Chief Financial Officer and Treasurer